Lec 16- Schizophrenia Flashcards
1
Q
Definitions
A
- Schizophrenia- also called
- Paranoid illness/ Delusional disorder/ Psychotic state/ Psychosis
- Drug-induced psychosis- Short term only
- Schizoaffective disorder
- Combination of bipolar and schizophrenia
- Psychotic depression
- Severely depressed & loss touch with reality
2
Q
Schizophrenia- frequency & epidemiology
A
- Lifetime expectation- 0.5-1.0%
- Onset usually late adolescence or early adult life
- Affects males and females equally
- Rate similar most countries
- Twice the rate in immigrants
3
Q
Thought abnormalities
A
- Thought interference includes
- Insertion
- Withdrawal
- Broadcasting- believe people can read you thought
- Block
- Knight’s move thinking- thinking about things that are totally unrelated
- Concrete thought- focus on physical facts
- The poverty of thought- not much thought
- Speech abnormalities
4
Q
Symptoms
A
- What is schizophrenia
- Lose touch with reality
- Reality subjective
- Abnormalities
- Thought
- Ideation (Delusions)
- Perception (Hallucinations)
- Emotion
5
Q
Other symptoms
A
- Delusion= false belief against reality e.g. believing you have “God-like” powers
- Hallucination = Disorder of perception
- 3rd person auditory most common
- Emotion- blunted; incongruity i.e. inappropriate
- Positive- delusions, thought disorder; hallucinations
- Negative symptoms- social withdrawal, apathy
6
Q
Treatment through the ages
A
- Insulin coma shock
- Psychosurgery
- ECT
- Neuroleptics
- Typicals
- Atypicals
7
Q
Insulin coma therapy
A
- The idea that you can’t get epilepsy and psychosis together (this is now known to be wrong), induce hypoglycaemia = seizures= treat psychosis
- Quite risky as very dangerous
- Large dose insulin induce coma & seizure
- Given glucose recovery
- Widely used 1930-1970
- Often led to serious illness & even death
8
Q
Psychosurgery
A
- 1930s “prefrontal Lobotomy” Portuguese physician Egas Moniz
- 1949- Nobel prize medicine
- US 10,000-20,000 patients 1930s- 1950s
- Adverse events- cognitive & emotional deficit
- Still limited use
9
Q
Electroconvulsive therapy (ECT)
A
- Introduced 1939 Cerletti- Italy
- Same theory as coma shock therapy= don’t get epilepsy and psychosis
- Production fit by electricity
- Never much help schizophrenia
- Effective severe depression
- It is hard to do clinical trials
10
Q
Anti-psychotics
A
- Typicals- Chlorpromazine, Trifluoperazine, Fluphenazine, Haloperidol, Flupenthixol, Zuclopenthixol
- Atypicals- Risperidone, Olazapine, Quetiapine, Aripiprazole, Clozapine
- Long acting preparations- depots/Consta
- Generally equally effective
11
Q
Efficacy
A
- Generally greater efficacy +ve symptoms (exceptions clozapine)
- Work in 3 ways
- Calming effect
- Immediate sedative compounds- not true anti-psychotic effect = As required usage
- Symptom control
- Symptom control can take 6-8 weeks- although some effects from 1 week
- Patience and support required
- Relapse prevention
- Maintenance treatment prevent re-lapse- long-term compliance
- Stop medication no immediate return symptoms
- Re-lapse delayed 2-6 months
12
Q
typical side effects
A
- Anti-cholinergic (also with atypicals)
- Dry mouth, blurred vision, constipation
- Often wear off
- Others- Lower seizure threshold (also atypicals)
- Numerous
- Movement problems- Main problem
- Acute dystonia
- Abnormal face & body movements e.g. stiff neck
- Potentially fatal
- oculogyric crisis- involuntary upward movement of eyes- Can be fatal medical emergency
- Parkinsonism- coarse tremor at rest, rigidity, slow movement
- Treatments
- Anticholinergics- procyclidine, benzhexol, benztropine
- Anti-cholinergic side effects; Abuse potential
13
Q
Typical side effects
A
- Akathisia
- Inner restlessness, floor pacing, crossing legs, very distressing
- Treatments: BZs; 5-HT antagonists- Cyproheptadine, mirtazapine/ mianserin
- Tardive Dyskinesia
- Late-onset involuntary & repetitive facial movements
- Lip smacking, grimacing
- Irreversible- no effective treatments
- A form of brain damage
14
Q
Depots
A
- Long-acting injection
- Flupenthixol decanoate; Haloperidol decanoate; Fluphenazine decanoate; Zuclopenthixol
- Given every 1-4 weeks
- Efficacy >4 months
- No more effective
- May aid compliance but
- Patients do not like depots
- Cause more movement problems
15
Q
Atypical neuroleptics
A
- Search agents without movement problems typicals
- Major advantage
- Little or no movement disorder
- Procyclidine type medicines not usually required
- NICE used to recommend first-line treatment
- Different side-effects- significant weight gain 5-10 Kg
- Patient preferred side-effects
- Monotherapy
- Long-term use- atypical + typical not recommended- double side effects
- Little evidence increase efficacy- clozapine
16
Q
Clozapine: efficacy
A
- Activity at many receptors- dirty drug
- Only anti-psychotic with proven increased efficacy
- reason unclear- due to broad activity
- Indicated in treatment-resistant schizophrenia
- Long-term medication
- Up to 1 year for a maximum response
17
Q
Clozapine: side effects
A
- Lack of EPSE
- Neutropenia (drop WBC)- also called agranulocytosis (severe drop)
- Risk of infection- fatalities reported
- Not dose dependent
- Most commonly w6-18
- Regular blood tests
- Blood results must be okay for drug dispensed
18
Q
Clozapine: other serious side-effects
A
- Weight gain- significant 10-20Kg
- Dietary advice; fruit and veg; reduce fatty food; exercise
- Tailored programmes, dietician support
- Diabetes
- Related weight gain
- Patients warned of signs
- Regular monitoring- oral glucose tolerance test (random), HbA1C
- May need insulin or oral agents
- Seizures
- Dose related- grdual titration; check plasma levels
- Doses >600mg DD consider valproate
- After seizure reduce damage
- Constipation
- 3 fatal cases
- Usual advice: high-fibre diet; plenty of fluids
- Laxatives may be required
19
Q
Clozapine: other serious side-effects
A
- Tachycardia
- Usually benign- treat with atenolol
- If persistent at rest + five; chest pain and hypotension could indicate myocarditis- stop clozapine and referral
- Hypersalivation
- Can be very distressing, usually nocturnal
- Plastic pillows but acceptability is an issue
- hyoscine 300mcg at night- OTC Kwells
- Other treatments- aantimuscarinics procyclidine, pirenzepine- not licensed in the UK
20
Q
Olanzapine
A
- Activity range receptors- D (including D2); 5-HT including (5-HTA), HI, Anti-cholinergic
- No evidence efficacy TRS
- Lack of EPS
- Significant weight gain
- Mean 10Kg or ore
- Distribution not uniform
- Diabetes, increase serum triglyceride/ ChE
- Regular monitoring- weight, others
- Long-term risk cardiac disease
21
Q
Risperidone
A
- High affinity: Serotoninergic 5-HT2 and dopaminergic D2 receptors + other activities
- Most effective dose 4-6mg daily- lower doses in older people
- Reduced EPSE at lower doses
- Less weight gain than olanzapine- usually 3-5Kg
- Initial hypotension
- Increase serum prolactin- leading to
- Galactorrhea, gynecomastia, amenorrhea
- Sexual side-effects e.g. impotence
- Risk osteoporosis
- Linked with breast cancer
22
Q
Risperidone consta
A
- First depot atypical
- Unique release mechanism
- No efficacy in resistant schizophrenia
- Movement problems occur higher doses
- Cold chain product- like a vaccine
- 36-step injection & re-constitution procedure
23
Q
Release mechanism
A
- Microsphere biodegradable polymer beads
- Degrade releasing over sustained period
24
Q
Quetiapine
A
- Affinity serotonin (5-HT2), dopamine D1 and D2 receptors
- Adrenergic H1
- Lack of EPSE
- No evidence efficacy in TRS
- Risk- weight gain
- Case reports- diabetes
25
Q
Aripiprazole
A
- Partial agonism D2, 5-HT1a receptors + antagonism 5-HT2a receptors
- Not particularly effective
- Less weight gain than other atypicals
- Adverse events include- Anxiety; insomnia; akathisia; nausea; vomiting
- Not recommended- treatment resistant
26
Q
A